지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Objective : This study was performed to determine the safety and outcome of concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide for Korean patients with a newly diagnosed glioblastoma. Methods : Patients were recruited from four institutions between 2004 and 2007. The patients received fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks and daily temozolomide, followed by 6 cycles of adjuvant temozolomide. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), response, and safety. Results : A total of 103 patients were enrolled in this study. Ninety-six patients (93%) completed the CCRT and 54 patients (52%) received 6 cycles of adjuvant temozolomide. The response rate was 73% (53/73) and the tumor control rate was 92% (67/73). Of the 96 patients who completed the CCRT, the median OS was 18.0 months and the 1- and 2-year OS rates were 74 and 38%, respectively. The median PFS was 10.0 months and the 1- and 2-year PFS rates were 33 and 16%, respectively. The only significant prognostic factor of survival was the extent of surgical resection (p<0.05). CCRT resulted in grade 3 or 4 hematologic toxic effects in 8% of patients. No opportunistic infections were noted. Conclusion : This study is the first prospective multi-institutional report of CCRT and adjuvant chemotherapy with temozolomide for patients with a newly diagnosed glioblastoma in Korea. The current protocol may prolong the survival of Korean patients with a glioblastoma and may be tolerable in terms of toxicity.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Brada M / 2001 / Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse / Ann Oncol 12:259~266
Chibbaro S / 2004 / Temozolomide as first-line agent in treating high-grade gliomas : phase II study / J Neurooncol 67:77~81
Jung-Won Choi / 2008 / The Outcomes of Concomitant Chemoradiotherapy Followed by Adjuvant Chemotherapy with Temozolomide for Newly Diagnosed High Grade Gliomas : The Preliminary Results of Single Center Prospective Study / 대한신경외과학회지 44(4):222~227
DeAngelis LM / 2001 / Brain tumors / N Engl J Med 344:114~123
Friedman HS / 1998 / DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma / J Clin Oncol 16:3851~3857
Chibbaro S / 2004 / Temozolomide as first-line agent in treating high-grade gliomas : phase II study / J Neurooncol 67:77~81
Jung-Won Choi / 2008 / The Outcomes of Concomitant Chemoradiotherapy Followed by Adjuvant Chemotherapy with Temozolomide for Newly Diagnosed High Grade Gliomas : The Preliminary Results of Single Center Prospective Study / 대한신경외과학회지 44(4):222~227
DeAngelis LM / 2001 / Brain tumors / N Engl J Med 344:114~123
Friedman HS / 1998 / DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma / J Clin Oncol 16:3851~3857
이 논문의 저자 정보
최근 본 자료
댓글(0)
0